Uses of Uperio

This is an automatically translated article.

1. What is the drug Uperio?

Uperio drug belongs to the group of cardiovascular drugs, which are prepared with many strengths and ingredients including:
Uperio 50mg Each tablet contains 24.3 mg sacubitril. 25.7 mg valsartan Uperio 100mg each tablet contains 48.6mg sacubitril and 51.4mg valsartan Uperio 200mg each tablet contains 97.2mg sacubitril and 102.8mg valsartan

2. Indications and contraindications

2.1 Indications for use of the drug Uperio Uperio is indicated for use in the treatment of symptomatic heart failure in patients with systolic dysfunction. Uperio has been shown to reduce hospital admissions for heart failure and cardiovascular mortality compared with enalapril. In addition, Uperio has also been shown to reduce mortality from many other causes compared with enalapril.
Besides the above uses, Uperio can also be used to treat a number of other conditions that are not listed above. Therefore, before taking the drug, consult your doctor for advice and effective use of the drug.
2.2 Contraindication to the use of the drug Uperio Contraindicated to use the drug Uperio to treat the following cases:
Hypersensitivity to the components of the drug Pregnant women History of angioedema related to receptor blockers angiotensin Severe liver failure Biliary cirrhosis Cholestasis

3. Usage and dosage of the drug Upio

The drug Uperio is made in the form of tablets, so it can be taken on an empty stomach or on an empty stomach. Patients should take the medicine with a full glass of water to avoid stomach irritation. Dosage of Uperio will depend on the condition and age of the patient such as:
The recommended starting dose is 100mg/day for patients who are not taking angiotensin-converting enzyme inhibitors or blockers. angiotensin II receptor, and is also considered for patients who have previously used these agents. Patients with systolic blood pressure ≥100-110 mmHg/ not taking ACEIs or angiotensin II receptor blockers/ previously taking these drugs at low doses: use/recommendation/consider initiation of 50 mg twice /day. Double dose every 2 to 4 weeks to target dose of 200 mg twice daily as tolerated. If systolic blood pressure ≤ 95 mmHg, symptomatic hypotension, clinically significant hyperkalemia, renal dysfunction: adjust dose of concomitant drugs, temporarily reduce dose/discontinue Uperio. Elderly patients: dose should be suitable for renal function, moderate or severe renal impairment, moderate hepatic impairment: starting dose is 50 mg twice daily, end-stage renal disease: not recommended. Children and adolescents < 18 years: Safety and efficacy have not been established. Use Uperio regularly to get the most benefit from it. To use it safely, take Uperio exactly as directed by your doctor, do not use it more often, smaller or longer than prescribed. Absolutely do not abuse the drug for too long for a long time or arbitrarily increase the dose of the drug. Because this not only makes the condition worse, but also increases the risk of unwanted effects.

4. Undesirable effects when using the drug Upio

Some unwanted effects that may occur when using Uperio include:
Lowering blood pressure Increased or decreased blood potassium Decreased kidney function Anemia Hypoglycemia Headache, dizziness, fainting, dizziness Cough Diarrhea Nausea Gastritis Fatigue, weakness Before prescribing medication, doctors always weigh the benefits and effectiveness of the drug Uperio more than the risk of side effects. However, in some cases, when using Upio, unwanted effects may still occur. Therefore, when there are unusual signs after taking the drug, especially when a severe allergic reaction occurs with accompanying signs such as difficulty breathing, severe dizziness, swelling, rash or itching of the face area. , throat, tongue,... In this case, the patient should immediately notify the medical staff for immediate intervention.

5. Some notes when using the drug Upio

Some notes when using Uperio include:
Inform your doctor about a history of allergy to Upio or any other allergies. Upperio may contain ingredients that don't work and could cause an allergic reaction or other serious problems. Report any medications you are taking including prescription and nonprescription drugs, herbs and supplements, foods, dyes or preservatives. Do not use Uperio within 36 hours of taking an ACEI. Evaluation of patients with heart failure should always include assessment of renal function. Patients with mild and moderate renal impairment are at increased risk for hypotension. Clinical experience is very limited in patients with severe renal impairment (estimated glomerular filtration rate (GFR) <30 ml/min/1.73 m2) and these patients are at greatest risk for hypotension. There is no experience in patients with end-stage renal disease and the use of Uperio is not recommended. Treatment should not be initiated if the serum potassium level is > 5.4 mmol/l. Use of Uperio may be associated with an increased risk of hyperkalemia, although hypokalemia may also occur. Monitoring of serum potassium is recommended, particularly in patients with risk factors such as renal failure, diabetes mellitus or hypoaldosteronism or who have a high potassium diet or are taking mineral corticosteroid antagonists. If the patient has clinically significant hyperkalemia, it is recommended to adjust the dose of the concomitant drugs or titrate the temporary dose reduction or discontinuation of the drug. Discontinuation of treatment should be considered if serum potassium levels are > 5.4 mmol/l. If angioedema occurs, Uperio should be discontinued immediately and appropriate treatment instituted and monitored until the clinical signs and symptoms have resolved. Uperio must not be used again. Where angioedema is localized to the face and lips, angioedema usually resolves on its own without treatment, although antihistamines can be used to relieve symptoms. Use of Upperio may be associated with renal function. This risk may be further increased by dehydration or concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs). Dosage reduction should be considered in patients who develop a clinically significant decrease in renal function. Like other drugs that affect the renin-angiotensin-aldosterone system, Uperio may increase blood urea and serum creatinine levels in patients with bilateral or unilateral renal artery stenosis. Caution is advised in patients with renal artery stenosis and monitoring of renal function is recommended. If you forget to take a dose, take the missed dose as soon as possible. However, if it is almost time for the next dose, skip the missed dose and continue taking the medicine as scheduled. Do not arbitrarily use the drug twice the dose more than the treatment regimen. Using an overdose of Uperio can cause serious symptoms such as nausea, vomiting, abdominal pain, weakness,... Especially hypotension because Uperio has the effect of lowering blood pressure.

6. Drug interactions

Drug interactions that can decrease the effectiveness of the drug Uperio , or increase the effect of unwanted effects. Tell your doctor about all other medicines you are taking including vitamins, over-the-counter medicines, prescription drugs, and herbal products. Do not stop, start, or change the dose of any medicine without your doctor's consent without your doctor's consent.
Some drugs that may interact with Uperio include:
Angiotensin-converting enzyme (ACE) inhibitors are contraindicated for concurrent use with Uperio because concomitant inhibition of neprilysin and ACE inhibitors may increase the risk of angioedema muscle. Uperio should not be started within 36 hours of taking the last dose of an ACE inhibitor. Also, do not start ACE inhibitor therapy within 36 hours of taking the last dose of Uperio. Aliskiren: Contraindicated with Uperio in patients with type 2 diabetes. Angiotensin II receptor blockers: due to the angiotensin II receptor blocking effect of Uperio. Statins: Due to Uperio, systemic exposure of OATP1B1 and OATP1B3 substrates such as statins may be increased. In addition, co-administration of a statin with Uperio doubled the cmax of atorvastatin and its metabolites and increased the AUC by 1.3-fold. PDE5 inhibitors including sildenafil: Concomitant administration of a single dose of sildenafil with steady-state Uperio in hypertensive patients produces a marked decrease in blood pressure. Therefore, caution should be exercised when initiating sildenafil or another PDE-5 inhibitor in a patient being treated with Uperio. Potassium: Concomitant use of potassium-sparing diuretics (eg, triamterene, amiloride), mineralocorticoid receptor antagonists (eg, spironolactone, eplerenone), potassium supplements, or potassium-containing salts may lead to lead to an increase in serum potassium and lead to an increase in serum creatinine. Monitoring of serum potassium levels is recommended if Uperio is co-administered with these agents (see PRECAUTIONS). Non-steroidal anti-inflammatory drugs (NSAIDs) including selective cyclooxygenase-2 inhibitors (COX-2 inhibitors): In elderly patients, volume-depleted patients (including patients) are on diuretic therapy), or in patients with impaired renal function, concomitant use of Uperio and NSAIDs may lead to an increased risk of worsening of renal function. Therefore, monitoring of renal function is recommended when initiating or changing the dose in patients receiving NSAIDs concomitantly with Uperio. Lithium: The potential for drug interactions between Uperio and lithium has not been studied. Reversible increases in serum lithium concentrations and toxicity have been reported with concomitant use of lithium with ACE inhibitors or angiotensin II receptor antagonists. Therefore, careful monitoring of serum lithium levels is recommended when co-administered with Uperio. If the same diuretic is used, the risk of lithium toxicity may be further increased. OATP and MRP2 transporters: The active metabolite of sacubitril (LBQ657) and valsartan is the substrate OATP1B1, OAT3; valsartan is also an MRP2 substrate. Therefore, co-administration of Uperio with OATP1B1, OATP1B3, OAT3 inhibitors (such as rifampin, cyclosporil) or MPR2 (such as ritonavir) may increase circulating levels of LBQ657 or valsartan, respectively. Care should be taken when starting and stopping treatment with these drugs. How to store Uperio medicine Store Uperio at room temperature, away from light and away from moisture. Do not store the Upperio in a humid place or in the freezer. Different medicines will have different ways to store them, so read the instructions on the packaging for Uperio carefully, or ask your pharmacist. Keep Uperio out of the reach of children and family pets. In summary, Uperio is effective in the treatment of symptomatic heart failure in patients with systolic dysfunction. At the same time, Uperio has been shown to reduce hospitalization and mortality from cardiovascular disease. However, Uperio can cause some unwanted effects and drug interactions, so tell your doctor what medications you are taking to reduce the risk of side effects and increase effectiveness. for the treatment.
Follow Vinmec International General Hospital website to get more health, nutrition and beauty information to protect the health of yourself and your loved ones in your family.

Please dial HOTLINE for more information or register for an appointment HERE. Download MyVinmec app to make appointments faster and to manage your bookings easily.